Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and raised its price target from $28.00 to $51.00 on shares of Zogenix, Inc.’s (NASDAQ: ZGNX) stock. The report follows the company’s release of positive topline data for its pivotal phase 3 trial of ZX008 in Dravet Syndrome – Study 1. The study reached its primary endpoint, representing that 0.8 mg/kg/day of ZX008 as an adjunctive therapy is greater than a placebo in reducing mean monthly convulsive seizure frequency. The results also validate ZX008s mechanism of action involving Sig-1R receptor. The analyst noted that the efficacy results are better than expected, which bodes well for ZX008 moving forward.
For more information, visit www.Zogenix.com
About Zogenix
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
